Glytec Adds New Wins in 1H 2024 to Drive Inpatient
Diabetes Market Momentum and Leadership
BOSTON, July 10,
2024 /PRNewswire/ -- Glytec, the only provider
of cloud-based insulin management Software as a Service (SaaS)
solutions across the continuum of care, proudly announces
significant new client partnerships in 1H 2024, reinforcing its
position as the market leader in meeting the needs of the growing
healthcare industry and diabetes technology market.
Glytec's market leadership and momentum was on display in 1H
2024, adding 11 new deals, including 2 new major clients, 3 health
system expansions, and 6 renewals from satisfied clients with an
average growth of 54%.
"These deals add to why over 350 hospitals recognize Glytec's
ability to address the top hospital challenges in 2024, including
patient safety, profitability and cost of care, nurse and provider
workflow, and revenue growth through increased patient throughput
and reduced ICU length of stay," stated Pat
Cua, Glytec CEO.
Hospitals are under increased pressure to improve patient safety
and outcomes in the area of diabetes care, as demonstrated by the
U.S. Centers for Medicare & Medicaid Services (CMS) proposed
mandate for hospitals to report incidences of severe hypoglycemia
and hyperglycemia, an area for which Glytec has long been an
advocate. Glytec's FDA-approved
Glucommander® solution and enhanced analytics have
demonstrated a 6-8x Return-On-Investment (ROI) for clients as
evidenced by studies showing an average 3.2 days reduction in ICU
length of stay,[1] a 99.8 percent reduction in frequency
of severe hypoglycemia,[2] a 35-68 percent reduction in
readmissions,[3] and annual savings of over 7 million dollars per 600 beds,[1]
amongst other independently verified findings.
Glytec's industry-leading software addresses timely, critical
challenges for the healthcare industry. One-third of all
hospitalized patients require insulin therapy to regulate high
blood sugar during their stay.[4] More than 2 million
patients each year experience an adverse event in the hospital
leading to hypoglycemia, costing the healthcare system over 8
billion dollars. Yet nearly one-third of hospitals have no glucose
management metrics, and 59 percent do not have an automated method
of pulling data on rates of hyperglycemia and
hypoglycemia.[5]
The market demand for Glucommander® is surging, and
these wins validate the growing market need for Glytec's current
and expanding suite of solutions.
About Glytec
Glytec's industry leading SaaS platform,
trusted by 350+ hospitals, empowers collaborative diabetes
management and insulin dosing, improving patient outcomes, reducing
length of stay, and streamlining workflows while delivering a 6-8x
ROI. The first-ever FDA-cleared cloud-based insulin management
software is EMR-integrated, easy to set up, and validated by over
100 patents and over 100 publications. The Glytec
Glucommander® solution, with clinical decision support,
workflow alerts, patient monitoring, at-risk patient
identification, and AI-driven analytics, is supported by a
mission-driven team dedicated to helping healthcare leaders,
clinicians and patients promote health equity and improve diabetes
outcomes from hospital to home. We are on a mission, join us.
For more information, follow Glytec on X
(@Glytec) and LinkedIn, or visit
www.glytec.com.
Sources
- Newsom, et al., "Safely Converting From Sliding Scale…" ADA
Sci Sessions. (Jun 2017).
[Link]
- Rabinovich, et al., J of Diab
Sci & Tech, 12, no. 1 (2018): 47–52.
https://doi.org/10.1177/1932296817747617
- Mumpower, et al., "Relationship Between Glycemic Control Using
eGMS…" Ann Diab Tech Mtg. (Nov
2016). [Link]
- Umpierrez, et al. J of Clin Endo &
Met. 87, no. 3 (March 2002):
978–82. https://doi.org/10.1210/jcem.87.3.8341.
- Cook, et al. End Pract. 16, no. 2
(March 2010):
219-30. https://doi.org/10.4158/EP09234.OR.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/glytec-announces-major-deals-and-continued-market-leadership-in-diabetes-care-302192738.html
SOURCE Glytec